Clinical trials: Esophageal Motility Disorders
Gastroesophageal Reflux Disease
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the…
- Trial name
- RESTORE500 (NCT07004439)
- Testing
- RefluxStop™ implantation
- Where
- 5 sites in Germany, Spain
- Volunteers
- 500 people
- Sponsor
- Implantica CE Reflux Ltd.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the safety and efficacy of Rabeprazole extended release (ER) 50 mg versus Esomeprazole 40 mg for healing and symptomatic relief among subjects with erosive gastroesophageal reflux disease…
- Trial name
- NCT00658528
- Testing
- Rabeprazole sodium, Esomeprazole
- Where
- 88 sites in United States, Argentina and 11 more
- Volunteers
- 1,061 people
- Sponsor
- Eisai Inc.
Non-erosive Reflux Disease
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease
The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4
- Trial name
- NCT02556021
- Testing
- CJ-12420 50mg, CJ-12420 100mg
- Where
- South Korea
- Volunteers
- 324 people
- Sponsor
- HK inno.N Corporation
Patients With Typical Symptoms of GERD (GERD Q >= 8)
Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.
China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients with Gastroesophageal Reflux Disease
- Trial name
- NCT02606851
- Where
- 10 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Endoscopically-Proven GERD, Reflux
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to determine the area under the plasma concentration-time curve (AUC) of esomeprazole after single oral doses of 5 mg, 10 mg or 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive…
- Trial name
- NCT00687245
- Testing
- esomeprazole magnesium
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD), Heartburn
Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
To compare the complete healing of erosive esophagitis(EE) after 3 weeks of treatment with Secretol 80/80 versus Nexium 40 mg daily.
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Indigestion
- Trial name
- NCT01129713
- Testing
- Secretol, Nexium
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Effexus Pharmaceutical
Gastroesophageal Reflux in Children
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.
- Trial name
- STELLAR (NCT04358146)
- Testing
- Experimental Infant formula, Infant formula thickened with locust bean gum
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 346 people
- Sponsor
- United Pharmaceuticals